4.6 Review

Cannabinoids and Epilepsy

Journal

NEUROTHERAPEUTICS
Volume 12, Issue 4, Pages 747-768

Publisher

SPRINGER
DOI: 10.1007/s13311-015-0375-5

Keywords

Epilepsy; seizures; cannabinoids; cannabidiol; THC; cannabis

Funding

  1. GW Pharmaceuticals
  2. National Institute of Mental Health [5R37MH071739]
  3. National Institute of Neurological Disorders and Stroke [5R01NS074785, 5R01NS024067]

Ask authors/readers for more resources

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Delta 9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available